Biomarkers and Pe...
Follow
Find
12.1K views | +0 today
Biomarkers and Personalized Medicine
Sharing relevant articles on advancements in personalized medicine
Curated by Brian Shields
Your new post is loading...
Your new post is loading...
Scooped by Brian Shields
Scoop.it!

Small Steps Add Up to Progress in NSCLC, a Clinical Context Report - MedPage Today

CHARLES BANKHEAD: I'm Charles Bankhead of MedPage Today, and this is Expert Commentary, Non-Small Cell Lung Cancer. My guest is Dr. Lecia Sequist of the Massachusetts General Hospital. She is a thoracic medical oncologist at the MGH Cancer Center and is also assistant professor of medicine at Harvard.

Thank you for joining us...

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

MRI may show migraine biomarker

MRI may show migraine biomarker | Biomarkers and Personalized Medicine | Scoop.it
MRI scans of migraine sufferers have revealed that the intense, throbbing headaches they suffer are related to brain abnormalities, some of which are present at birth and others that develop over time, according to a study published online March 26...
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Circulating Tumor DNA | Now@NEJM

Circulating Tumor DNA | Now@NEJM | Biomarkers and Personalized Medicine | Scoop.it

Fifty years ago, oncologists relied upon the clinical exam to follow breast cancer patients with metastatic disease. Patients were treated with chemotherapy, and then the physicians waited for symptoms to return before deciding on the next treatment course. Some patients could go months or even years without symptoms, but during this time they played a waiting game. Technology did not yet exist to allow physicians to detect cancer progression in the absence of overt clinical clues.

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Next-Gen DNA sequencing advances rare disease diagnosis

Next-Gen DNA sequencing advances rare disease diagnosis | Biomarkers and Personalized Medicine | Scoop.it

THE first publication on the use of WA’s Lotterywest Next-Gen sequencing platform in a human context has been released, revealing two novel genetic aberrations that lead to the onset of a devastating neuromuscular disease in utero.

Equally significant is proof that the latest sequencing technology can be used successfully and cost-effectively in gene discovery and diagnosis of rare disease cases.

Neuromuscular disease experts, Dr Gina Ravenscroft and Professor Nigel Laing from the Western Australian Institute for Medical Research (WAIMR), and clinicians and pathologists in Western and South Australia, have identified two new variants of a gene, known to regulate glycogen availability for muscle development.

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Immunohistochemical Biomarkers in Gastric Cancer Research and Management

Immunohistochemical Biomarkers in Gastric Cancer Research and Management | Biomarkers and Personalized Medicine | Scoop.it
International Journal of Surgical Oncology is a peer-reviewed, open access journal that publishes original research articles, review articles, and clinical studies in all areas of surgical oncology.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Emory receives NINDS grant for biomarker research on Parkinson's - News-Medical.net

Emory receives NINDS grant for biomarker research on Parkinson's
News-Medical.net
Led by F.
Brian Shields's insight:

Some exciting news coming out of my alma mater, Emory University.  The goal of this research is to "achieve a better prognosis for patients by identifying neuro-degeneration earlier", according to F. DuBois Bowman, PhD, the leader of the grant initiative.

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Is CT Analysis of Tumors a Biomarker for Esophageal Cancer?

Is CT Analysis of Tumors a Biomarker for Esophageal Cancer? | Biomarkers and Personalized Medicine | Scoop.it
ORLANDO—CT texture analysis of primary tumors may be a potential imaging biomarker in localized esophageal cancer following neoadjuvant chemotherapy, according to research being presented at the 2013 Cancer ...
Brian Shields's insight:

Important info for a difficult to treat cancer, esophageal cancer.  The use of imaging may help physicians determine the best treatment choice for patients.

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Genomics at your fingertips: DNA Sequencing in the Primary Care Office - The Doctor Weighs In

Genomics at your fingertips: DNA Sequencing in the Primary Care Office - The Doctor Weighs In | Biomarkers and Personalized Medicine | Scoop.it
RT @EricTopol: Genomics at Your Fingertips http://t.co/iehVcVfP by @drkevincampbell HT @cyphergenomics #CDoM
Brian Shields's insight:

Interesting article on the possible future development of sequencing in the primary care office.  The article builds off a new technology reported by Anne Eisenberg in a recent NY Times article. This technology from a company called Knome, allows a single Lab or office to sequence a person's genome.  The technology costs about $125,000.

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

DAI provides potential imaging biomarker to indicate brain tumor response to RT - Medical Xpress

DAI provides potential imaging biomarker to indicate brain tumor response to RT - Medical Xpress | Biomarkers and Personalized Medicine | Scoop.it
DAI provides potential imaging biomarker to indicate brain tumor response to RT Medical Xpress Diffusion abnormality index (DAI) shows promise as an imaging biomarker to measure brain tumor response to radiation therapy, according to research being...
Brian Shields's insight:


This is a positive step forward in providing patients with more accurate treatment decisions when Radiation therapy is used to treat brain tumors.


This Biomarker is a new diffusion index, DAI, which could potentially indicate post-treatment tumor response.

"While this review included a small number of patients, the data demonstrate that DAI may be a good biomarker to predict brain tumor response," said lead study author Reza Farjam, a PhD candidate in biomedical engineering focused on cancer functional imaging at the University of Michigan in Ann Arbor, Mich. "Further study of this method is needed to improve early prediction of tumor response to radiation therapy and to help us provide brain cancer patients with more accurate information about their treatment progress."

Read more at: http://medicalxpress.com/news/2013-02-dai-potential-imaging-biomarker-brain.html#jCp


more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Matching Tumors With The Optimal Cancer Drugs - Science 2.0

Matching Tumors With The Optimal Cancer Drugs - Science 2.0 | Biomarkers and Personalized Medicine | Scoop.it
Matching Tumors With The Optimal Cancer Drugs
Science 2.0
The main driver of pancreatic cancer, a mutation in a gene called KRAS, has proven difficult to target with treatments.
Brian Shields's insight:

Very Powereful Quote and an important one for clinicians to understand, " We have a small but effective inventory of 'druggable' mutations that we know play a role in cancer"

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

What’s in a Name? A Lot, When It Comes to ‘Precision Medicine’ | Xconomy

What’s in a Name? A Lot, When It Comes to ‘Precision Medicine’ | Xconomy | Biomarkers and Personalized Medicine | Scoop.it
Personalized medicine was supposed to be the pot of gold at the end of the rainbow. It was going to be the payoff our society would see after investing in (Precision vs. Personalized medicine is gaining corporate momentum.
Brian Shields's insight:

Precision Medicine is a new and growing term used to describe the precision that diagnostics may allow in identying and treating diseases.

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Genetic landscape of common brain tumors holds key to personalized treatment - EurekAlert (press release)

Exciting information on the recognition of the NF2 gene as a target for treatment of meningiomas
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Personalized Regulation: More Than Just Personalized Medicine -- And ... - Forbes

Personalized Regulation: More Than Just Personalized Medicine -- And ... - Forbes | Biomarkers and Personalized Medicine | Scoop.it
Very important article reviewing the need to provide patients with choices, yet also balancing the need to fully present the risk benefit ratio of new products.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

EGFR Mutation Not a Prognostic Factor for NSCLC

EGFR Mutation Not a Prognostic Factor for NSCLC | Biomarkers and Personalized Medicine | Scoop.it
Although the presence of an EGFR mutation is a predictive marker for response to EGFR tyrosine kinase inhibitor therapy in patients with non-small cell lung cancer, the mutation is not a prognostic factor.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Multiple Sclerosis Research: Research Biomarker for Progression

Multiple Sclerosis Research: Research Biomarker for Progression | Biomarkers and Personalized Medicine | Scoop.it

Multiple sclerosis (MS) is a central nervous system (CNS) disorder characterised by demyelination and neurodegeneration. Although hallmarks of recovery (remyelination and repair) have been documented in early MS, the regenerative capacity of the adult CNS per se remains uncertain with the wide held belief that it is either limited or non-existent. The neural cell adhesion molecule (NCAM) is a cell adhesion molecule that has been widely implicated in axonal outgrowth, guidance and fasciculation. Here, we used in vitro and in vivo studies in MS to investigate the role of NCAM in disease progression.

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

New test could help detect pancreatic cancer early

A new diagnostic test that uses metabolomic analysis may be a safe and easy screening method to detect pancreatic cancer, researchers in Japan said.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Pfizer's Xalkori And The Progress In Lung Cancer Drugs

Pfizer's Xalkori And The Progress In Lung Cancer Drugs | Biomarkers and Personalized Medicine | Scoop.it
Lung cancer is a tricky disease and there is a graveyard littered with lung cancer drugs that failed in clinical trial.Targeted approaches like Xalkori from Pfizer (PFE) and Tarceva from Roche (RHHBY.OB) work for small segmen...
Brian Shields's insight:

Very good insight on the current targeted options available for lung cancer patients and the promising products in development such as Dacomitinib and Reolysin.  The article notes that the molecular testing rate in Lung Cancer is now 60%, a growth from 10% at the launch of Xalkori.

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

EGFR’s Evolution: New Insights Refine Role of Mutation in NSCLC

EGFR’s Evolution: New Insights Refine Role of Mutation in NSCLC | Biomarkers and Personalized Medicine | Scoop.it
Despite all we have learned about the importance of sensitizing EGFR mutations in defining the management of advanced NSCLC, our education regarding the relevance of this molecular target in optimizing clinical outcomes continues.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

How Genomics Is Changing Clinical Outcomes: Q&A with Heidi Rehm | New York Genome Center

How Genomics Is Changing Clinical Outcomes: Q&A with Heidi Rehm | New York Genome Center | Biomarkers and Personalized Medicine | Scoop.it

Heidi Rehm has been using disease-targeted gene panels to diagnose patients in her clinical molecular genetics practice for a decade. Having adopted next-generation sequencing approaches two years ago, and whole-genome and whole-exome sequencing for some patients in the past year, she is a pioneer in applying genomics in the clinic.

Brian Shields's insight:

Very good discussion on the current impact that genetic and genomic sequencing are having on clinical decisions, and a look into the future when  genome analysis is much more cost effective.


more...
No comment yet.
Rescooped by Brian Shields from Digital Health
Scoop.it!

Watson now officially fighting cancer, from the cloud

Watson now officially fighting cancer, from the cloud | Biomarkers and Personalized Medicine | Scoop.it
IBM is turning Watson loose on lung cancer, offering up a cloud-based service designed to let doctors from around the country find the best-possible treatments for their patients.

Via Alex Butler
Brian Shields's insight:

Very exciting to see the leaders in tech partner with the leaders in cancer care.  I believe the next revolution in medicine will be driven by technology and the front line health care and research institutes.


Aggregating and utilizing data intelligently will help clinicians and reseachers better provide care to the community.  The lines between research trials and the standards of care may gradually blur as new technology driven treatment strategies emerge.

more...
Laurent FLOURET's curator insight, August 20, 2014 5:32 AM

"Sloan-Kettering is also training Watson on 1,500 real-world lung cancer cases, helping it to decipher physician notes and learn from the hospital’s expertise in treating cancer."

Scooped by Brian Shields
Scoop.it!

BATTLE-2: Next-Generation of Biomarker-Driven Trials - OncLive

BATTLE-2: Next-Generation of Biomarker-Driven Trials - OncLive | Biomarkers and Personalized Medicine | Scoop.it
OncLive BATTLE-2: Next-Generation of Biomarker-Driven Trials OncLive While the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific...
Brian Shields's insight:

The next-generation of clinical trials...Powerful quote in this article from Dr. Roy Herbst:


Are clinical trials like this going to be the wave of the future for developing new cancer therapies?

Herbst: Absolutely. I think it’s essential. If you don’t let the biology drive the treatment, everything is empiricism and it is going to have a very low chance of hitting the mark. So absolutely, as Dr Wistuba said, treat patients the best you can in real time, but also learn, discover, identify new markers.



This trial uses biomarkers to guide decisions, thereby providing patients with the best possible treatment arm, despite randomization.

more...
Nalina Nagarajan's curator insight, April 17, 2013 12:14 PM

A necessary development !!

Scooped by Brian Shields
Scoop.it!

New Drug Is First to Help Patients With Recurrent Low-Grade Ovarian Cancer - Science Daily (press release)

New Drug Is First to Help Patients With Recurrent Low-Grade Ovarian Cancer Science Daily (press release) Cancer-causing genetic mutations in BRAF and KRAS genes occur more frequently in low-grade ovarian cancer, so the researchers chose a drug that...
Brian Shields's insight:

Researchers identified that KRAS and BRAF mutations occur more frequently in low grade Ovarian cancer and chose a therapy (Selumetinib) that inhibits the molecular network, MAPK, that includes these genes. 


The outcome:


"These are remarkably encouraging results for what can ultimately be a devastating disease," said Gershenson, the paper's senior author.

more...
Erin Grills's curator insight, February 23, 2013 10:04 PM

This site will allow me to discuss the advancements in drugs for my pharmaceutical subtopic. This also allows me to expand my research to see how many other cancer drugs are being discovered due to the advancemens in engineering.

Scooped by Brian Shields
Scoop.it!

Check Up: DNA test analyzes genes known to contribute to cancer

Check Up: DNA test analyzes genes known to contribute to cancer | Biomarkers and Personalized Medicine | Scoop.it
Embracing the promise of personalized medicine, Fox Chase Cancer Center is offering a high-tech DNA test that can identify the genetic mutations driving an individual patient's cancer.
Brian Shields's insight:

This is a great step forward in the treatment of cancer by Fox Chase Cancer Center.  Hopefully in the future, similar offerings will become the standard of care.

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Researchers Identify Biomarker and Potential Therapy Target in MS ...

Researchers Identify Biomarker and Potential Therapy Target in MS ... | Biomarkers and Personalized Medicine | Scoop.it
Researchers discover proteins in the IL-6 signaling pathway may be leveraged as novel biomarkers of multiple sclerosis (MS) to gauge disease activity and as a target for new therapies.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Will ASCO GI herald a new era for pancreatic cancer?

Very important medical conference today in my backyard, ASCO GI. Sally Church reviews why the data presented at this meeting may finally yield an improvement in the treatment of Pancreatic Cancer.
more...
No comment yet.